C. Catalani

发表

The N-terminal of icatibant and bradykinin interact with the same Asp residues in the human B2 receptor.

C. Maggi, L. Rotondaro, S. Zappitelli, 2004, European journal of pharmacology.

Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.

C. Maggi, L. Rotondaro, M. Altamura, 2004, European journal of pharmacology.

A different molecular interaction of bradykinin and the synthetic agonist FR190997 with the human B2 receptor: evidence from mutational analysis

C. Maggi, L. Rotondaro, W. Reichert, 2003, British journal of pharmacology.

Antagonism of Bradykinin B2 Receptor Prevents Inflammatory Responses in Human Endothelial Cells by Quenching the NF-kB Pathway Activation

C. Maggi, S. Donnini, M. Ziche, 2014, PloS one.

Comparison of the molecular interactions of two antagonists, MEN16132 or icatibant, at the human kinin B2 receptor

C. Maggi, L. Rotondaro, S. Zappitelli, 2011, British journal of pharmacology.

Pharmacological profile of the novel mammalian tachykinin, hemokinin 1

C. Maggi, A. Lecci, L. Quartara, 2002, British journal of pharmacology.

MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.

C. Maggi, L. Rotondaro, A. Lecci, 2005, European journal of pharmacology.

Radioligand binding characterization of the bradykinin B(2) receptor in the rabbit and pig ileal smooth muscle.

C. Maggi, P. Santicioli, S. Meini, 2010, European journal of pharmacology.

Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts

C. Maggi, S. Meini, F. Bellucci, 2009, British journal of pharmacology.

Bradykinin and B2 receptor antagonism in rat and human articular chondrocytes

C. Maggi, S. Meini, F. Bellucci, 2011, British journal of pharmacology.

Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.

C. Maggi, L. Rotondaro, S. Zappitelli, 2005, European journal of pharmacology.

MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.

C. Maggi, A. Lecci, R. Catalioto, 2006, European journal of pharmacology.

Characterization of ibodutant at NK(2) receptor in human colon.

P. Bechi, C. Maggi, P. Santicioli, 2013, European journal of pharmacology.

Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays.

C. Maggi, P. Santicioli, S. Meini, 2009, European journal of pharmacology.

Comparative antagonist pharmacology at the native mouse bradykinin B2 receptor: radioligand binding and smooth muscle contractility studies

C. Maggi, P. Santicioli, S. Meini, 2007, British journal of pharmacology.

Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E2 release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes

C. Maggi, A. Fioravanti, M. Galeazzi, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

Pharmacological evaluation of α and β human tachykinin NK2 receptor splice variants expressed in CHO cells

C. Maggi, L. Rotondaro, A. Faiella, 2004 .

Synovial fluid levels of bradykinin correlate with biochemical markers for cartilage degradation and inflammation in knee osteoarthritis.

C. Maggi, A. Fioravanti, G. Guidelli, 2013, Osteoarthritis and cartilage.

The effect of GABApentin on neurogenic detrusor overactivity, a pilot study

A. Tubaro, G. Palleschi, A. Carbone, 2003 .

Multifaceted Approach to Determine the Antagonist Molecular Mechanism and Interaction of Ibodutant ([1-(2-Phenyl-1R-{[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl}-ethylcarbamoyl)-cyclopentyl]-amide) at the Human Tachykinin NK2 Receptor

P. Santicioli, S. Meini, A. Giolitti, 2009, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.

C. Maggi, L. Rotondaro, A. Faiella, 2004, European journal of pharmacology.

Fasitibant prevents the bradykinin and interleukin 1β synergism on prostaglandin E2 release and cyclooxygenase 2 expression in human fibroblast-like synoviocytes

C. Maggi, A. Fioravanti, M. Galeazzi, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

Site-directed mutagenesis at the human B2 receptor and molecular modelling to define the pharmacophore of non-peptide bradykinin receptor antagonists.

C. Maggi, L. Rotondaro, A. Faiella, 2004, Biochemical pharmacology.

Characterization of ibodutant at NK(2) receptor in human colon.

P. Santicioli, S. Meini, C. Catalani, 2013, European journal of pharmacology.

P. Santicioli, S. Meini, A. Giolitti, 2009, Journal of Pharmacology and Experimental Therapeutics.